8-K

                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549


                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                        Date of Report: November 20, 2003


                           MOLECULAR DIAGNOSTICS, INC.
               (Exact Name of Company as Specified in Its Charter)


          Delaware                     0-935                   36-4296006
(State or other Jurisdiction  (Commission File Number)       (IRS Employer
     Of Incorporation)                                    Identification Number)



                            414 NORTH ORLEANS STREET
                                    SUITE 510
                             CHICAGO, ILLINOIS 60610

              (Address and Zip Code of Principal Executive Offices)

                                 (312) 222-9550

              (Registrant's telephone number, including area code)





Item 5.  Other Events and Required FD Disclosures

         A copy of a press release issued by the Company on November ___, 2003
announcing its termination of licenses previously granted by subsidiaries to
MonoGen, Inc. is attached as Exhibit 99 to this Current Report on Form 8-K and
is incorporated herein by reference.

Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits


         Exhibit Number          Description
         --------------          -----------
         99                      Press release dated November 20, 2003


                                    SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                        MOLECULAR DIAGNOSTICS, INC.


                                        /s/  Peter P. Gombrich
                                        ------------------------------------
                                        Peter P Gombrich
                                        Chairman and Chief Executive
                                        Officer

Date: November 20, 2003

EX-99

[LOGO] MOLECULAR DIAGNOSTICS

                                                                   PRESS RELEASE
                                                           For immediate release

                     [LETTERHEAD OF MOLECULAR DIAGNOSTICS]


 MOLECULAR DIAGNOSTICS, INC. SUBSIDIARIES TERMINATE LICENSES WITH MONOGEN, INC.

                 Also Amends Complaint Against Former Executive


         CHICAGO, ILLINOIS, November 20, 2003. Molecular Diagnostics, Inc.
(OTCBB:MCDG)("MDI"), together with its subsidiaries, AccuMed International, Inc.
("AccuMed") and Oncometrics Imaging Corp. ("Oncometrics"), announced today that
the licenses granted by AccuMed and Oncometrics to MonoGen, Inc. ("MonoGen"),
Vernon Hills, Illinois, for the limited use of certain technologies in the field
of cancer detection, have been terminated by AccuMed and Oncometrics as a result
of the licenses' invalidity. MDI believes that the termination of these
licenses, which were entered into prior to its acquisition of AccuMed and
Oncomtrics, will eliminate the confusion promulgated by MonoGen's claims of
rights to the technologies and will enhance MDI's business opportunities
surrounding those technologies. Additionally, this action allows MDI to proceed
with possible action against other parties that might be in violation of MDI
patents.


         MDI and its subsidiaries are currently suing the former officer of
AccuMed and Oncometrics whose responsibility it was to negotiate the licenses
with MonoGen on behalf of those companies. This suit, which was filed in the
Circuit Court of Cook County, Illinois, is predicated on the actions of the
former officer, who left his positions with AccuMed and Oncometrics shortly
after negotiating the MonoGen licenses to become the President of MonoGen. The
suit alleges that, as part of the negotiations, MDI and the British Columbia
Cancer Agency (BCCA), which originally developed a portion of the technologies,
believe the officer knowingly negotiated below-market license fees from MonoGen,
and knew at the time that BCCA had not given its consent for the MonoGen
transactions. It is the position of MDI and its subsidiaries that such behavior
on the part of the former officer was a breach of his fiduciary duties to
AccuMed and Oncometrics and created violations under the BCCA license
agreements.


About Molecular Diagnostics, Inc.

Molecular Diagnostics develops cost-effective cancer screening systems, which
can be utilized in a laboratory or at the point-of-care, to assist in the early
detection of cervical, gastrointestinal, and other cancers. The InPath System is
being developed to provide medical practitioners with a highly accurate,
low-cost, cervical cancer screening system that can be integrated into existing
medical models or at the point-of-care. Other products include SAMBA(TM)
Telemedicine software used for medical image processing, database and multimedia
case management, telepathology and teleradiology. Molecular Diagnostics also
makes certain aspects of its technology available to third parties for
development of their own screening systems.

More information is available at: www.Molecular-Dx.com
                                  --------------------

Certain statements in this release are forward-looking. These statements are
based on Molecular Diagnostics' current expectations and involve many risks and
uncertainties, such as the company's inability to obtain sufficient financing,
the possibility that clinical trials will not substantiate Molecular
Diagnostics' expectations with respect to the InPath(TM) System, and other
factors set forth in reports and documents filed by Molecular Diagnostics with
the Securities and Exchange Commission. Actual results may differ materially
from Molecular Diagnostic's current expectations depending upon a number of
factors affecting the Company's business. These factors include, among others,
risks and uncertainties detailed in the Company's periodic public filings with
the Securities and Exchange Commission, including but not limited to the
Company's Annual Report on Form 10-K for the year ended December 31, 2002 and
its Quarterly Report on Form 10-QSB for the quarter ended September 30, 2003.
Except as expressly required by law, Molecular Diagnostics undertakes no
obligation to publicly update or revise any forward-looking statements contained
herein.